Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML (GITMO-AMLR2)
Randomized Study Comparing i.v. Busulfan (Busilvex®) Plus Fludarabine (BuFlu) Versus Busilvex® Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age >= 40 and =<65 Years) With AML in Complete Remission.
Sponsor: Gruppo Italiano Trapianto di Midollo Osseo
This PHASE3 trial investigates Acute Myeloid Leukemia (AML) and is currently completed. Gruppo Italiano Trapianto di Midollo Osseo leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Apr 2023 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gruppo Italiano Trapianto di Midollo Osseo
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alessandria, Italy , Ancona, Italy , Bari, Italy , Bergamo, Italy , Bolzano, Italy , Brescia, Italy , Catania, Italy , Cuneo, Italy , Florence, Italy , Genova, Italy and 13 more locations